| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7M | — | — |
| R&D Expense | $26.8M | — | +7.0% |
| SG&A Expense | $11.1M | — | +13.1% |
| Operating Income | -$34.2M | — | +2.0% |
| Net Income | -$24.4M | — | -3.6% |
| EPS (Basic) | -$0.39 | — | -2.6% |
| EPS (Diluted) | -$0.39 | — | -2.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $51.8M | -1.0% | -29.7% |
| Short-term Investments | $904.6M | -1.1% | -3.8% |
| Accounts Receivable | $35.0M | — | — |
| Current Assets | $1.00B | +2.7% | -2.1% |
| Total Assets | $1.03B | +2.7% | -2.1% |
| Current Liabilities | $58.9M | +135.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.3M | — | +27.5% |
| Capital Expenditures | $273K | — | -26.4% |
| Investing Cash Flow | $8.3M | — | +102.4% |
| Financing Cash Flow | $3.5M | — | +539.9% |
| Free Cash Flow | -$12.6M | — | +27.5% |
| +236.6% |
| Total Liabilities | $86.7M | +93.8% | +126.3% |
| Stockholders' Equity | $941.5M | -1.6% | -7.0% |